VISEN Pharmaceuticals (SEHK: 2561)
Health Care · Biotechnology · CN
HK$20.00
+0.10% today · -58.6% 1Y
VISEN Pharmaceuticals (SEHK: 2561) operates in the Biotechnology industry within the Health Care sector. The company is valued at $277.89M and employs 82 people.
Over the last twelve months the share price has lost 58.6%, trading between 18.50 and 50.60.
Tweenvest scores VISEN Pharmaceuticals across four factors: quality 28/100, value 43/100. Its strongest factor is value.
2561 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $277.89M
- Revenue (TTM)
- $19.44K
- P/E
- —
- EPS
- -2.44
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$50.60
- 52-week low
- HK$18.50
- Avg volume (3M)
- —
- Shares outstanding
- 109.04M
- Employees
- 82
- Next earnings
- —
About VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
- ISIN
- KYG93Y5D1039
- Founded
- 2018
- Listed since
- Mar 21, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.